Merz Pharma controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2024
FDA warning over Xeomin Instagram advertisement
The U.S. Food and Drug Administration objected to an Instagram advertisement featuring Nate Berkus in connection with Xeomin. The agency said that claims concerning the product’s rapid effects and unique benefits lacked adequate supporting evidence and that the presentation of risk information was insufficient, making the communication misleading.
2021
Merz sues MSN over generic Cuvposa application
Lawsuit filed
Merz Pharmaceuticals filed a complaint against MSN Pharmaceuticals, alleging that MSN's application to market a generic version of Merz's Cuvposa would infringe Merz's drug patent. Merz sought an injunction against commercial manufacture, use, sale, offer for sale, or importation of the generic product.
Source excerpt
On Thursday, Merz Pharmaceuticals LLC (Merz) filed a complaint against fellow pharmaceutical company MSN Pharmaceuticals Inc. (MSN) for allegedly infringing its drug patent by seeking to make a generic version of Merz’s drug Cuvposa.
The plaintiff requests that its accusation of infringement is affirmed and that there is an injunction enjoining MSN, and all persons acting in concert with MSN, from the commercial manufacture, use, sale, offer for sale, or importation into the United States of MSN’s ANDA Products, or any other drug product whose use is covered by the patent.